Sensorion SA (EPA:ALSEN)
France · Delayed Price · Currency is EUR 0.2280
-0.0045 (-1.94%)
Sep 11, 2026, 5:35 PM CET
Sensorion Earnings Call Transcripts
Fiscal Year 2025
-
Sensorion is advancing gene therapies for hearing loss, with SENS-501 in Phase 1/2 showing early safety and behavioral improvements, and GJB2 progressing toward clinical trials. Strategic partnerships, a robust natural history network, and a focus on young patients differentiate its approach.